Erratum to: Allergy Asthma Clin Immunol (2016) 12:11 DOI 10.1186/s13223-016-0110-8
After publication of the article [1] it was brought to our attention that the incorrect length of needle was used for one of the epinephrine auto-injectors (EAI), Jext®. The length of the needle of the Jext® 0.15 mg is not 15.7 mm as mentioned in the paper, but 13 mm. After correcting the needle length for Jext®, the results of the study do not change aside for those involving Jext®. The results of the primary outcome variable for Jext® are now the same as the other high pressure EAIs (HPEAIs) and do not lead to intra-osseous injections 38% but 11% between 15 and 30 kg. This is the same risk as the Epipen® and the Auvi-Q®.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Footnotes
The online version of the original article can be found under doi:10.1186/s13223-016-0110-8.
Contributor Information
Sten Dreborg, Email: sten.dreborg@telia.com.
Xia Wen, Email: shawn.wen0507@gmail.com.
Laura Kim, Email: laurakimkw@gmail.com.
Gina Tsai, Email: gyctsai@yahoo.ca.
Immaculate Nevis, Email: immaculatenevis@yahoo.ca.
Ryan Potts, Email: rhpotts29@gmail.com.
Jack Chiu, Email: jacchiu@gmail.com.
Arunmozhi Dominic, Email: arundominic5@gmail.com.
Harold Kim, Email: hlkimkw@gmail.com.
Reference
- 1.Dreborg S, Wen X, Kim L, Tsai G, Nevis I, Potts R, Chiu J, Dominic A, Kim H. Do epinephrine auto-injectors have an unsuitable needle length in children and adolescents at risk for anaphylaxis from food allergy? Allergy Asthma Clin Immunol. 2016;12:1. doi: 10.1186/s13223-016-0110-8. [DOI] [PMC free article] [PubMed] [Google Scholar]